Notes
Gynecologic Oncology Group
Reference
Cohn DE, et al. A cost-utility analysis of an NRG Oncology/Gynecologic Oncology Group Protocol 218: Incorporating prospectively collected Quality-of-life scores in an economic model of treatment of ovarian cancer. Gynecologic Oncology : 23 Oct 2014. Available from: URL: http://doi.org/10.1016/j.ygyno.2014.10.020
Rights and permissions
About this article
Cite this article
Bevacizumab not worth it, even after adjusting for QOL impact. PharmacoEcon Outcomes News 718, 13 (2014). https://doi.org/10.1007/s40274-014-1778-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1778-y